{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:39Z","timestamp":1786136019660,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03009-9","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:55:02Z","timestamp":1786089302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver fibrosis risk: a silent threat in type 1 diabetes mellitus"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5051-9116","authenticated-orcid":false,"given":"Sabri Engin","family":"Alt\u0131ntop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Barlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiye Cenay Karabork","family":"K\u0131l\u0131c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recep Emre","family":"Sabur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Kart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujde","family":"Akt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusun Balos","family":"Toruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev Eroglu","family":"Alt\u0131nova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"3009_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","author":"F Tacke","year":"2024","unstructured":"Tacke F (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"issue":"9","key":"3009_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"3009_CR3","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/eje-20-0065","volume":"183","author":"MM Ruissen","year":"2020","unstructured":"Ruissen MM, Mak AL, Beuers U, Tushuizen ME, Holleboom AG (2020) Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur J Endocrinol 183(3):R57-r73. https:\/\/doi.org\/10.1530\/eje-20-0065","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"3009_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/ejendo\/lvae043","volume":"190","author":"CM Fuhri Snethlage","year":"2024","unstructured":"Fuhri Snethlage CM, Meijnikman AS, Mak AL, Rampanelli E, Voermans B, Callender CAK et al (2024) Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes. Eur J Endocrinol 190(5):391\u2013400. https:\/\/doi.org\/10.1093\/ejendo\/lvae043","journal-title":"Eur J Endocrinol"},{"key":"3009_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.09.038","author":"M Souza","year":"2024","unstructured":"Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A (2024) Global epidemiology and characteristics of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.038","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"3009_CR6","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","volume":"105","author":"M de Vries","year":"2020","unstructured":"de Vries M, Westerink J, Kaasjager K, de Valk HW (2020) Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 105(12):3842\u20133853. https:\/\/doi.org\/10.1210\/clinem\/dgaa575","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3009_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/m22-3078","volume":"176","author":"M Fang","year":"2023","unstructured":"Fang M, Jeon Y, Echouffo-Tcheugui JB, Selvin E (2023) Prevalence and management of obesity in U.S. adults with type 1 diabetes. Ann Intern Med 176(3):427\u2013429. https:\/\/doi.org\/10.7326\/m22-3078","journal-title":"Ann Intern Med"},{"issue":"4","key":"3009_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K (2019) From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 1(4):312\u2013328. https:\/\/doi.org\/10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"issue":"8","key":"3009_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/j.1464-5491.2010.03035.x","volume":"27","author":"M Venturini","year":"2010","unstructured":"Venturini M, Angeli E, Maffi P, Losio C, Pozzi P, Paties C et al (2010) Liver focal fatty changes at ultrasound after islet transplantation: an early sign of altered graft function? Diabet Med 27(8):960\u2013964. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03035.x","journal-title":"Diabet Med"},{"issue":"32","key":"3009_CR10","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S (2016) Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand? World J Gastroenterol 22(32):7236\u20137251. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7236","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3009_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03160-8","volume":"24","author":"M Wang","year":"2024","unstructured":"Wang M, Tang S, Li G, Huang Z, Mo S, Yang K et al (2024) Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients. BMC Gastroenterol 24(1):81. https:\/\/doi.org\/10.1186\/s12876-024-03160-8","journal-title":"BMC Gastroenterol"},{"key":"3009_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1571487","volume":"12","author":"H Zou","year":"2025","unstructured":"Zou H, Pan W, Sun X (2025) Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts. Front Nutr 12:1571487. https:\/\/doi.org\/10.3389\/fnut.2025.1571487","journal-title":"Front Nutr"},{"key":"3009_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.848937","volume":"13","author":"C Zhu","year":"2022","unstructured":"Zhu C, Huang D, Ma H, Qian C, You H, Bu L et al (2022) High-sensitive CRP correlates with the severity of liver steatosis and fibrosis in obese patients with metabolic dysfunction associated fatty liver disease. Front Endocrinol (Lausanne) 13:848937. https:\/\/doi.org\/10.3389\/fendo.2022.848937","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3009_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goad059","author":"AP Okekunle","year":"2023","unstructured":"Okekunle AP, Youn J, Song S, Chung GE, Yang SY, Kim YS et al (2023) Predicted pro-inflammatory hs-CRP score and non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf). https:\/\/doi.org\/10.1093\/gastro\/goad059","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"3009_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230x-6-33","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3009_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM et al (2021) Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 41(2):261\u2013270. https:\/\/doi.org\/10.1111\/liv.14669","journal-title":"Liver Int"},{"issue":"3","key":"3009_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/2050640619900820","volume":"8","author":"G Semmler","year":"2020","unstructured":"Semmler G, W\u00f6ran K, Scheiner B, Unger LW, Paternostro R, Stift J et al (2020) Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. United Eur Gastroenterol J 8(3):321\u2013331. https:\/\/doi.org\/10.1177\/2050640619900820","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"3009_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D et al (2019) Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156(6):1717\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042","journal-title":"Gastroenterology"},{"key":"3009_CR19","doi-asserted-by":"publisher","DOI":"10.11152\/mu-4491","author":"F Liu","year":"2025","unstructured":"Liu F, Zeng H, Yuan X, Du L, Wu X, Han X et al (2025) Ultrasound Attenuation, Liver Texture Index, and HepatoRenal Index: Assessing Reproducibility and Inter-operator Consistency in Clinical Practice. Med Ultrason. https:\/\/doi.org\/10.11152\/mu-4491","journal-title":"Med Ultrason"},{"issue":"5","key":"3009_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101684","volume":"51","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Ciardullo S, Sani E, Csermely A, Shtembari E, Milani I et al (2025) Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study. Diabetes Metab 51(5):101684. https:\/\/doi.org\/10.1016\/j.diabet.2025.101684","journal-title":"Diabetes Metab"},{"issue":"12","key":"3009_CR21","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/dme.12805","volume":"32","author":"JM Petit","year":"2015","unstructured":"Petit JM, Pedro L, Guiu B, Duvillard L, Bouillet B, Jooste V et al (2015) Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis. Diabet Med 32(12):1648\u20131651. https:\/\/doi.org\/10.1111\/dme.12805","journal-title":"Diabet Med"},{"issue":"4","key":"3009_CR22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004","journal-title":"Hepatology"},{"issue":"1","key":"3009_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s2468-1253(22)00317-x","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH et al (2023) Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8(1):20\u201330. https:\/\/doi.org\/10.1016\/s2468-1253(22)00317-x","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3009_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13(2):134\u2013148. https:\/\/doi.org\/10.1016\/s2213-8587(24)00318-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3009_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00649-0","volume":"13","author":"BSV Barros","year":"2021","unstructured":"Barros BSV, Monteiro FC, Terra C, Gomes MB (2021) Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. Diabetol Metab Syndr 13(1):33. https:\/\/doi.org\/10.1186\/s13098-021-00649-0","journal-title":"Diabetol Metab Syndr"},{"issue":"7","key":"3009_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100753","volume":"5","author":"J Mertens","year":"2023","unstructured":"Mertens J, Weyler J, Dirinck E, Vonghia L, Kwanten WJ, Mortelmans L et al (2023) Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. JHEP Rep 5(7):100753. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100753","journal-title":"JHEP Rep"},{"issue":"8","key":"3009_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1055\/a-1666-0431","volume":"130","author":"G Meyer","year":"2022","unstructured":"Meyer G, Dauth N, Grimm M, Herrmann E, Bojunga J, Friedrich-Rust M (2022) Shear wave elastography reveals a high prevalence of NAFLD-related fibrosis even in type 1 diabetes. Exp Clin Endocrinol Diabetes 130(8):532\u2013538. https:\/\/doi.org\/10.1055\/a-1666-0431","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"3009_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00535-007-2152-7","volume":"43","author":"K Iwamoto","year":"2008","unstructured":"Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S et al (2008) Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 43(4):298\u2013304. https:\/\/doi.org\/10.1007\/s00535-007-2152-7","journal-title":"J Gastroenterol"},{"issue":"Suppl 2","key":"3009_CR29","doi-asserted-by":"publisher","first-page":"S775","DOI":"10.1016\/j.dsx.2017.05.015","volume":"11","author":"NG Vallianou","year":"2017","unstructured":"Vallianou NG, Kazazis C, Ioannidis G (2017) Diabetic hepatosclerosis: true clinical entity or ghost disease? Diabetes Metab Syndr 11(Suppl 2):S775\u2013S776. https:\/\/doi.org\/10.1016\/j.dsx.2017.05.015","journal-title":"Diabetes Metab Syndr"},{"key":"3009_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.958428","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Li L, Xu Y, Du J, Ling C (2022) Roles of hepatic stellate cells in NAFLD: from the perspective of inflammation and fibrosis. Front Pharmacol 13:958428. https:\/\/doi.org\/10.3389\/fphar.2022.958428","journal-title":"Front Pharmacol"},{"key":"3009_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00943","volume":"10","author":"A Pathak","year":"2019","unstructured":"Pathak A, Agrawal A (2019) Evolution of C-reactive protein. Front Immunol 10:943. https:\/\/doi.org\/10.3389\/fimmu.2019.00943","journal-title":"Front Immunol"},{"issue":"6","key":"3009_CR32","doi-asserted-by":"publisher","first-page":"E795","DOI":"10.1152\/ajpendo.00293.2024","volume":"329","author":"A Mingione","year":"2025","unstructured":"Mingione A, Loretelli C, Cas MD, Pivari F, Barcella M, Merelli I et al (2025) Lipidome profile of cystic fibrosis-related diabetes, type 1 and type 2 diabetes mellitus: potential links to inflammation and glucose and lipid metabolism. Am J Physiol Endocrinol Metab 329(6):E795-e809. https:\/\/doi.org\/10.1152\/ajpendo.00293.2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"3009_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jgh.13814","volume":"33","author":"L Svikl\u0101ne","year":"2018","unstructured":"Svikl\u0101ne L, Olmane E, Dz\u0113rve Z, Kup\u010ds K, P\u012br\u0101gs V, Sokolovska J (2018) Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol 33(1):270\u2013276. https:\/\/doi.org\/10.1111\/jgh.13814","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"3009_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00592-025-02611-2","volume":"63","author":"G Rossi","year":"2026","unstructured":"Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P (2026) Muscle loss and GLP-1R agonists use. Acta Diabetol 63(2):333\u2013342. https:\/\/doi.org\/10.1007\/s00592-025-02611-2","journal-title":"Acta Diabetol"},{"issue":"4","key":"3009_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gutjnl-2025-336127","volume":"75","author":"Z Huo","year":"2026","unstructured":"Huo Z, Chen Y, Huang Y, Yang Z, Long Y, Zhang Q et al (2026) Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut 75(4):772\u2013785. https:\/\/doi.org\/10.1136\/gutjnl-2025-336127","journal-title":"Gut"},{"issue":"5","key":"3009_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/hep.0000000000000323","journal-title":"Hepatology"},{"issue":"1","key":"3009_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12072-017-9840-z","volume":"12","author":"A Singh","year":"2018","unstructured":"Singh A, Le P, Lopez R, Alkhouri N (2018) The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int 12(1):37\u201343. https:\/\/doi.org\/10.1007\/s12072-017-9840-z","journal-title":"Hepatol Int"},{"issue":"2","key":"3009_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108405","volume":"37","author":"MD Lundholm","year":"2023","unstructured":"Lundholm MD, Bena J, Zhou K, Tsushima Y, Kashyap SR (2023) Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes. J Diabetes Complicat 37(2):108405. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108405","journal-title":"J Diabetes Complicat"},{"key":"3009_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1019899","volume":"9","author":"GH Zhang","year":"2022","unstructured":"Zhang GH, Yuan TH, Yue ZS, Wang L, Dou GR (2022) The presence of diabetic retinopathy closely associated with the progression of non-alcoholic fatty liver disease: a meta-analysis of observational studies. Front Mol Biosci 9:1019899. https:\/\/doi.org\/10.3389\/fmolb.2022.1019899","journal-title":"Front Mol Biosci"},{"key":"3009_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.823277","volume":"8","author":"TH Yuan","year":"2021","unstructured":"Yuan TH, Yue ZS, Zhang GH, Wang L, Dou GR (2021) Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects. Front Mol Biosci 8:823277. https:\/\/doi.org\/10.3389\/fmolb.2021.823277","journal-title":"Front Mol Biosci"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03009-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03009-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03009-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:03:25Z","timestamp":1786133005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-03009-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":40,"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03009-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Gazi University Clinical Research Ethics Committee (Decision No: 904). The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}